Bio-Rad Laboratories (BIO.B) vs Globus Medical (GMED)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Bio-Rad Laboratories (BIO.B) has outperformed Globus Medical (GMED) over the past year, gaining 28.2% versus a gain of 25.2%. Over five years, GMED leads with a -2.3% price change compared with -50.5% for BIO.B. Globus Medical is the larger company by market cap ($10.02 billion vs $9.76 billion), about 1.0 times the size.
On valuation, Globus Medical trades at a lower trailing P/E (19.1x vs 46.3x for Bio-Rad Laboratories). Bio-Rad Laboratories converts more of its revenue into profit, with a net margin of 29.4% versus 18.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIO.B | GMED |
|---|---|---|
| Share price | $365.08 | $74.65 |
| Market cap | $9.76B | $10.02B |
| 1-day change | 0.00% | +1.80% |
| YTD return | +17.50% | -14.50% |
| 1-year return | +28.15% | +25.23% |
| 5-year return | -50.54% | -2.33% |
| P/E ratio (TTM) | 46.27 | 19.14 |
| Forward P/E | — | 13.83 |
| EPS (TTM) | $7.89 | $3.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.58B | $2.94B |
| Revenue growth (YoY) | +0.65% | +16.65% |
| Net income (latest FY) | $759.90M | $537.87M |
| Gross margin | 51.87% | 67.41% |
| Operating margin | 1.83% | 16.33% |
| Net margin | 29.42% | 18.30% |
| 52-week high | $365.08 | $101.40 |
| 52-week low | $244.54 | $56.66 |
| Distance from 52-week high | 0.00% | -26.38% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +35.19% |
| Average volume | 4 | 1.51M |
| Shares outstanding | 5.06M | 111.83M |
| Employees | 7,450 | 6,000 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bio-Rad Laboratories trades at a higher earnings multiple (46.3x vs 19.1x trailing P/E).
- Bio-Rad Laboratories is more profitable, keeping 29.4 cents of every revenue dollar as net income versus 18.3 cents for Globus Medical.
- Globus Medical grew revenue faster in its latest fiscal year (+16.65% vs +0.65%).
About Bio-Rad Laboratories
BIO.B stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Healthcare · Medical Devices · 7,450 employees
About Globus Medical
GMED stock →Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.
Healthcare · Medical Devices · 6,000 employees
BIO.B vs GMED FAQ
Which is bigger, Bio-Rad Laboratories or Globus Medical?
Globus Medical (GMED) is larger, with a market capitalization of $10.02B compared with $9.76B for Bio-Rad Laboratories (BIO.B).
Which stock has performed better over the past year, BIO.B or GMED?
BIO.B returned +28.15% over the past 12 months, compared with +25.23% for GMED (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BIO.B or GMED?
GMED has the lower trailing P/E at 19.1, versus 46.3 for BIO.B. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Bio-Rad Laboratories and Globus Medical in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.